Pulmonary Arterial Hypertension
📧 Sign up to get email alerts when something new happens for Pulmonary Arterial Hypertension.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2014-05-20FDA Approved: OPSUMIT — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
The FDA approved a supplemental application for OPSUMIT (macitentan) submitted by Actelion Pharmaceuticals US, Inc.
-
FDA approval · 2014-05-06FDA Approved: ADEMPAS — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA approved a supplemental application for ADEMPAS (riociguat) submitted by Bayer HealthCare Pharmaceuticals Inc. The action pertains to th…
-
FDA approval · 2014-05-05FDA Approved: LETAIRIS — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for LETAIRIS (ambrisentan) submitted by Gilead Sciences, Inc.
-
CLINICAL_TRIALS trial_result · 2014-05-05Clinical Trial Update: Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension [Phase 3]
A Phase 3 trial evaluating macitentan in patients with symptomatic pulmonary arterial hypertension has completed, with results posted in 201…
-
FDA approval · 2014-04-29FDA Approved: ADCIRCA — Supplemental Application (United Therapeutics Corporation)
FDA approved a supplemental application for ADCIRCA (tadalafil) filed by United Therapeutics Corporation.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2014-04-09Clinical Trial Update: Resynchronisation Therapy of Right Ventricle in Pulmonary Arterial Hypertension [NA]
Update on a clinical trial evaluating right-ventricle resynchronisation therapy for pulmonary arterial hypertension; no phase or status info…
-
CLINICAL_TRIALS trial_result · 2014-04-09Clinical Trial Update: Long-term Study of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension Who Completed AIR001-CS05 [Phase 2]
Aires Pharmaceuticals reports termination of a long-term Phase 2 study of AIR001 in adults with WHO Group 1 pulmonary arterial hypertension …
-
CLINICAL_TRIALS trial_result · 2014-04-09Clinical Trial Update: A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH) [Phase 2]
A Phase 2 study evaluating AIR001 for pulmonary arterial hypertension was terminated; no results are provided in the document.
-
CLINICAL_TRIALS trial_result · 2014-04-03Clinical Trial Update: Trimetazidine in Pulmonary Artery Hypertension [Phase 2]
Phase 2 clinical trial update evaluating trimetazidine for pulmonary arterial hypertension; current status is unknown.
-
CLINICAL_TRIALS trial_result · 2014-03-31Clinical Trial Update: Efficacy and Safety Study of Sodium Tanshinone IIA Sulfonate on Pulmonary Hypertension [Phase 2, Phase 3]
This document describes an efficacy and safety study of Sodium Tanshinone IIA Sulfonate for pulmonary hypertension, including Phase 2 and Ph…
-
CLINICAL_TRIALS trial_result · 2014-03-17Clinical Trial Update: Multidisciplinary Collaboration Care in Pulmonary Arterial Hypertension (PAH) [NA]
This entry provides an update on a completed clinical trial evaluating multidisciplinary care approaches for pulmonary arterial hypertension…
-
FDA approval · 2014-03-11FDA Approved: SILDENAFIL CITRATE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for sildenafil citrate from Mylan Pharmaceuticals, authorizing a generic sildenafil citrate product.…
-
FDA approval · 2014-03-11FDA Approved: REVATIO — Supplemental Application (PFIZER LABORATORIES DIV PFIZER INC)
The FDA approved a supplemental NDA for Revatio (sildenafil citrate) submitted by Pfizer Laboratories Div Pfizer Inc.
-
FDA approval · 2014-03-11FDA Approved: REVATIO — Supplemental Application (Viatris Specialty LLC)
The FDA approved a supplemental application for Revatio (sildenafil citrate) filed by Viatris Specialty LLC.
-
FDA approval · 2014-03-11FDA Approved: REVATIO — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental application for REVATIO (sildenafil citrate) submitted by Viatris Specialty LLC.
-
FDA label_change · 2014-03-06FDA Approved: REVATIO — Supplemental Application (PFIZER LABORATORIES DIV PFIZER INC)
The FDA approved a supplemental application for Revatio (sildenafil citrate) from Pfizer Laboratories Div Pfizer Inc.
-
FDA approval · 2014-03-06FDA Approved: REVATIO — Supplemental Application (Viatris Specialty LLC)
The FDA approved a supplemental application for REVATIO (sildenafil citrate) filed by Viatris Specialty LLC.
-
FDA approval · 2014-03-06FDA Approved: REVATIO — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental application for REVATIO (sildenafil citrate) submitted by Viatris Specialty LLC. The action expands the approved…
-
CLINICAL_TRIALS trial_result · 2014-03-05Clinical Trial Update: Bosentan for Mild Pulmonary Vascular Disease in Asd Patients. [Phase 3]
A Phase 3 clinical trial evaluating bosentan for mild pulmonary vascular disease in patients with atrial septal defect has completed.
-
CLINICAL_TRIALS trial_result · 2014-02-27Clinical Trial Update: Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH) [Phase 2]
Phase 2 trial evaluating the efficacy, safety, tolerability, and pharmacokinetics of nilotinib in pulmonary arterial hypertension was termin…
-
CLINICAL_TRIALS trial_result · 2014-02-27Clinical Trial Update: Study of the Initial Combination of Bosentan With Iloprost in the Treatment of Pulmonary Hypertension Patients [Phase 3]
This document reports an update on a Phase 3 clinical trial evaluating the initial combination of bosentan and iloprost for pulmonary arteri…
-
CLINICAL_TRIALS trial_result · 2014-02-26Clinical Trial Update: A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH) [Phase 3]
Phase 3 trial update for an oral BAY63-2521 in patients with pulmonary arterial hypertension (PAH) has completed with results posted in 2014…
-
CLINICAL_TRIALS withdrawal · 2014-02-13Clinical Trial Update: Combined Use of Angiography, Optical Coherence Tomography and Intravascular Ultrasound in Evaluation of Pulmonary Vascular Structure and Function in Patients With Pulmonary Arterial Hypertension Treated With Oral Bosentan [Phase 4]
A Phase 4 clinical trial evaluating combined imaging modalities in pulmonary arterial hypertension using bosentan has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2014-02-04Clinical Trial Update: Pulmonary Hypertension and Imatinib
A completed clinical trial evaluating imatinib for pulmonary arterial hypertension, sponsored by The Cleveland Clinic.
-
CLINICAL_TRIALS trial_result · 2014-02-04Clinical Trial Update: Study of Cicletanine for Pulmonary Arterial Hypertension (PAH) [Phase 2]
Phase 2 study of cicletanine for pulmonary arterial hypertension was terminated.